F1000Res. 2017 Feb 14;6:139. doi: 10.12688/f1000research.10193.1. eCollection 2017.
PMID:28299192
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.
Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC.
EClinicalMedicine. 2024 Aug 30;75:102782. doi: 10.1016/j.eclinm.2024.102782. eCollection 2024 Sep.
PMID:39281096
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group.
Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575.
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA.